Accordingly, based on complementary mechanisms of action, the effects of combining ABBV-176 with the PARP inhibitor ABT-888 (Veliparib) were investigated in the CTG-0670 TNB BRCA1 deficient, BRCA2 mutant PDX tumor models. The gene discussed is BRCA1; the disease is neoplasm.